# A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

> **NCT05375604** · PHASE1 · TERMINATED · sponsor: **Codiak BioSciences** · enrollment: 9 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)
- Gastric Cancer Metastatic to Liver
- Colorectal Cancer Metastatic to Liver

## Interventions

- **DRUG:** CDK-004

## Key facts

- **NCT ID:** NCT05375604
- **Lead sponsor:** Codiak BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-28
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-05-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Company Bankruptcy
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375604, "A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05375604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*